Published 1 day ago • loading... • Updated 15 hours ago

Actithera Joins Radiopharmaceutical Boom with $75.5M Series A - Boston ...

On July 9, 2025, Actithera, a radiopharmaceutical biotech firm headquartered in Oslo and Cambridge, successfully secured $75.5 million in a heavily subscribed Series A funding round.
The funding round was jointly led by M Ventures along with new leading investors specializing in life sciences, providing support for the clinical progression of the company’s primary candidate targeting fibroblast activation protein .
Actithera develops small-molecule radioligands designed to improve tumor targeting, extend tumor residence, and enable rapid clearance to reduce toxicity in radioligand therapies .
Dr. Andreas Goutopoulos explained that their goal was to apply principles from small-molecule drug development, focusing on structural and kinetic insights, to enhance the design of radiopharmaceutical therapies.
The funding will allow Actithera to advance clinical trials starting in 2026 across multiple oncology indications, reflecting growing investor confidence in radiopharmaceutical therapies.

Insights by Ground AI

Does this summary seem wrong?

12 Articles

All

Left

Center

Right

The Business Journals

Center

Actithera joins radiopharmaceutical boom with $75.5M Series A - Boston ...

20 hours ago·United States

Read Full Article

Pharmaphorum

Center

New radiopharma Actithera emerges with $75.5m in financing

A new player in radioligand therapies, Actithera, has arrived on the scene with $75.5m in funding and lead FAP-targeted candidate for cancer.

21 hours ago

Read Full Article

Globe Newswire

Reposted by

4biocapital-new

Center

4BIO Capital co-leads Actithera’s oversubscribed $75.5 million Series A financing

4BIO investing in unique radiopharmaceutical platform company, developing radioligands with prolonged tumour retention Series A was co-led by 4BIO...

22 hours ago

Read Full Article

PR Newswire

Reposted by

Eastern Progress

Center

Actithera Raises $75.5M in Oversubscribed Series A Financing to Redefine Precision Radioligand Therapy

Series A co-led by founding investor M Ventures and new lead investors Hadean Ventures, Sofinnova Partners, and 4BIO Capital with syndicate including Bioqube...

22 hours ago·United States

Read Full Article

biopharmadive.com

Center

Actithera draws new investors to radiopharma drug pitch

The four-year-old biotech raised about $75 million in a Series A round that involved nine venture capital firms.

1 day ago

Read Full Article

pressreach.com

Actithera Raises $75.5M in Oversubscribed Series A Financing to Redefine Precision Radioligand Therapy - PressReach

Series A co-led by founding investor M Ventures and new lead investors Hadean Ventures, Sofinnova Partners, and 4BIO Capital with syndicate including Bioqube Ventures, Surveyor Capital and others Led by founder and drug discovery expert Dr. Andreas Goutopoulos, Actithera’s proprietary three-pillar discovery platform is designed to enable prolonged radioligand tumor retention Proceeds will support clinical development of Actithera’s fibroblast …

15 hours ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year